The Institute of Technology in Immunobiologicals of the Oswaldo Cruz Foundation (Bio-Manguinhos/Fiocruz) received last night (17) another shipment of the active pharmaceutical ingredient (IFA) that serves as the basis for the production of the Oxford/AstraZeneca vaccine against covid -19.
The API was imported from China, as foreseen in the Fiocruz agreement with pharmaceutical company AstraZeneca, and arrived on a flight to Rio de Janeiro.
The Ministry of Health confirmed the arrival of the IFA via Twitter.
#HEALTH NEWS Saturday and how are we? Receiving reinforcements Enough raw material has just arrived in RJ for the production of 10 MILLION AstraZeneca/Fiocruz vaccines, the most applied immunizing agent in Brazilians. There are already almost 76 million doses distributed throughout the country!
— Ministry of Health (@minsaude) July 17, 2021
The shipment will allow the production of 10 million doses. Bio-Manguinhos is still waiting for more IFA shipments for its production to reach the 100.4 million doses provided for in the contract with AstraZeneca.
This week, the foundation reached the milestone of 70.4 million doses produced in Bio-Manguinhos and delivered to the National Immunization Program. Another 4 million doses were imported ready-made from India at the beginning of the year.
By the end of the year, Fiocruz expects to receive IFA to produce over 70 million doses, in addition to the 100.4 million already contracted. In addition, the first national batch of API is in the production process, from which Fiocruz should gain self-sufficiency in the process and produce another 50 million doses this year and 180 million next year.
+ Learn about the effectiveness of each vaccine against Covid-19